期刊
AMERICAN JOURNAL OF CARDIOLOGY
卷 108, 期 2, 页码 308-316出版社
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjcard.2011.03.041
关键词
-
资金
- National Institutes of Health, Bethesda, Maryland
- GlaxoSmithKline, Research Triangle Park, North Carolina
- Merck & Company, Whitehouse Station, New Jersey
- Roche Diagnostics GmbH, Mannheim, Germany
- Pfizer, Inc., New York, New York
- AstraZeneca, Wilmington, Delaware
- B. Braun Medical, Inc., Bethlehem, Pennsylvania
- GenomaS, Inc., Hartford, Connecticut
- Hoffman-LaRoche Ltd.
- Basel, Switzerland
- Novartis, Basel, Switzerland
Hypertension is a major risk factor for cardiovascular disease, but control of hypertension remains inadequate, often because of poor patient adherence to prescribed medical regimens that are viewed as poorly tolerated and expensive. Physicians have largely stopped using some older blood pressure medications in favor of newer agents, mostly because of a presumed more favorable side effect profile. The investigators reviewed the pharmacologic properties and the evidence supporting the effectiveness and tolerability of several older blood pressure drugs: sympatholytic agents such as reserpine, methyldopa, and clonidine; diuretics such as chlorthalidone, ethacrynic acid and spironolactone; the vasodilators hydralazine and minoxidil; and others. In conclusion, some of these drugs are well studied and represent alternatives for patients who cannot afford or tolerate newer medications. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;108:308-316)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据